CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4α and DGAT2 expression.
Stefanie Y TanHannah C LittleDylan C SarverPaul A WatkinsG William WongPublished in: FEBS letters (2020)
C1q/TNF-related protein 12 (CTRP12) is an antidiabetic adipokine whose circulating levels are reduced in obesity and diabetes. Although partial and complete loss-of-function mouse models suggest a role for CTRP12 in modulating lipid metabolism and adiposity, its effect on cellular lipid metabolism remains poorly defined. Here, we demonstrate a direct action of CTRP12 in regulating lipid synthesis and secretion. In hepatoma cells and primary mouse hepatocytes, CTRP12 treatment inhibits triglyceride synthesis by suppressing glycerophosphate acyltransferase (GPAT) and diacylglycerol acyltransferase (DGAT) expression. CTRP12 treatment also downregulates the expression of hepatocyte nuclear factor-4α (HNF-4α) and its target gene microsomal triglyceride transfer protein (MTTP), leading to reduced very-low-density lipoprotein (VLDL)-triglyceride export from hepatocytes. Consistent with the in vitro findings, overexpressing CTRP12 lowers fasting and postprandial serum triglyceride levels in mice. These results underscore the important function of CTRP12 in lipid metabolism in hepatocytes.
Keyphrases
- low density lipoprotein
- nuclear factor
- poor prognosis
- liver injury
- type diabetes
- insulin resistance
- fatty acid
- cardiovascular disease
- drug induced
- rheumatoid arthritis
- mouse model
- induced apoptosis
- copy number
- blood glucose
- gene expression
- adipose tissue
- immune response
- body mass index
- cell proliferation
- inflammatory response
- cell cycle arrest
- protein protein
- replacement therapy